Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.20.

A number of research firms have issued reports on PYXS. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Guggenheim raised their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Zacks Research lowered Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Finally, Stephens lifted their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th.

Pyxis Oncology Stock Performance

Shares of PYXS opened at $1.15 on Friday. The business’s fifty day moving average price is $3.59 and its two-hundred day moving average price is $2.37. The firm has a market capitalization of $71.60 million, a price-to-earnings ratio of -0.72 and a beta of 1.45. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd bought a new position in Pyxis Oncology during the 2nd quarter worth approximately $26,000. Kingstone Capital Partners Texas LLC acquired a new stake in Pyxis Oncology in the second quarter worth $37,000. XTX Topco Ltd bought a new position in shares of Pyxis Oncology during the second quarter worth $40,000. Velan Capital Investment Management LP acquired a new position in shares of Pyxis Oncology in the 2nd quarter valued at $44,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Pyxis Oncology in the 3rd quarter valued at $77,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.